Dolby Laboratories

DLB Industrials Specialty Business Services

Dolby Laboratories' revenue for fiscal 2025 (year ended September 2025) was $1.3 billion, up 5.92% from fiscal 2024.

Revenue
−3.34%
EPS
−37.5%
Free cash flow
+157.4%

Quarter to June 2026, against a year earlier

64.77 1.45 +2.29%
Market cap
$5.9B
P/E
26.7×
Fwd P/E
20.0×
Dividend yield
2.26%
F-score
6/9
Altman Z
9.17
Beneish M
−2.80
Dividend safety
85/100

Dolby Laboratories (DLB) valuation and DCF model

What the price implies · reverse DCF

At $64.77 the price implies free cash flow after share-based pay growing 7.9% a year for ten years.

Free cash flow after share-based pay grew 16.8% a year over the last ten years, −1.0% over the last five. The price asks for less than its ten-year rate. The industry’s median company is priced for 14.5%.

In September 2017 the price assumed 9.2% a year; Dolby Laboratories went on to grow free cash flow after share-based pay 4.8% a year to FY2025.

Price implies
7.9%
Last 5 years, reported
−1.0%
Last 10 years, reported
16.8%
Industry median implies
14.5%

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
The price needs
7.9% a year for ten years
$64.77
today’s price
Its base case
16.8% a year for five years, then 10.1%
$96.34
48.7% above today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record Dolby Laboratories’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to June 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

Today’s price implies free cash flow after share-based pay growing 7.9% a year for ten years.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
negative is net cash
new shares the cash flow does not pay for

Against Dolby Laboratories’s own cost of capital: risk-free 4.3% + beta 0.77 × equity premium 4.5% = 7.8% cost of equity; weighted, 7.8%.

Use 7.8%
Equity value $9.25b ▲ above market cap $6.22b
Base case value per share $96.34 equity value ÷ 96.01m shares
Current price $64.77 market price per share
Above today’s price 48.7% upside at the base case’s assumptions

How we got there$3.11b 10 years of cash to equity+$5.40b terminal value+$739.54m net cash=$9.25b equity value÷96.01m shares=$96.34 per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Specialty Business Services).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E 26.74× 31.16× 41.88× 36% below 25.69× 4% above
P/FCF 16.61× 21.45× 23.25× 29% below 16.50× 1% above
P/B 2.31× 2.81× 2.88× 20% below 2.31× 0% above
EV/EBITDA 15.36× 18.40× 17.95× 14% below 11.75× 31% above
EV/Sales 3.88× 4.70× 4.91× 21% below 1.57× 147% above
15.04×17.54×20.05×22.55×10Y avg 17.95×2017201820192020202120222023202420252026

DLB trades at 15.36× EV/EBITDA, against a 10-year average of 17.95× (range 14.98×–22.67×). That is cheaper than 89% of the last 9 year-end readings; re-rating to the average implies $74.41 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.